infecti
diseas
continu
caus
suffer
death
teem
world
almost
billion
peopl
everi
individu
vulner
microbi
infect
regardless
socioeconom
statu
gender
age
group
ethnic
background
increas
intern
air
travel
mass
tourism
expans
global
meant
diseaseproduc
pathogen
transport
spread
rapidli
one
geograph
region
anoth
dramat
demonstr
sudden
complet
unexpect
multicountri
outbreak
sever
acut
respiratori
syndrom
sar
begin
atyp
pneumonia
caus
human
coronaviru
led
world
health
organ
issu
except
global
alert
caution
travel
certain
countri
unfold
tragedi
aid
particularli
mani
develop
nation
continu
vividli
highlight
scientif
public
media
accord
current
estim
million
peopl
viru
carrier
around
new
case
hiv
occur
daili
tuberculosi
infect
caus
ravag
nineteenth
centuri
resurg
sever
infecti
agent
neurolog
variant
creutzfeldtjakob
diseas
europ
vectorborn
west
nile
viru
usa
vancomycinresist
form
bacteria
japan
virul
avian
influenza
human
hong
kong
emerg
public
health
concern
past
yearsth
sheer
adapt
destruct
infecti
microb
pose
threat
unforeseen
diseas
centuri
accord
world
health
organ
least
new
diseas
emerg
past
two
decad
underscor
need
vigil
antimicrobi
drug
instrument
save
live
million
peopl
worldwideth
antibiot
magic
cure
previou
year
howev
steadili
erod
emerg
drugresist
microorgan
shown
advers
effect
control
treatment
deadli
diseas
caus
mycobacterium
tuberculosi
plasmodium
falciparum
acut
respiratori
infect
children
mostli
caus
pneumococci
haemophilu
influenza
becom
drugresist
staphylococcu
aureu
strain
pneumococci
strain
resist
penicillin
introduc
salmonella
typhi
streptococcu
pneumonia
enterococcu
faecium
shigella
dysenteria
report
multidrugresist
crucial
drug
choic
treatment
common
infect
bacteria
virus
parasit
fungi
becom
limit
even
nonexist
case
develop
parallel
effect
increas
discoveri
new
medicin
microbi
pathogen
struggl
control
infecti
diseas
far
acquir
new
poignanc
novel
concept
act
adjunct
establish
therapi
urgent
need
immun
system
manipul
specif
vaccin
nonspecif
immunomodul
immunomodul
includ
immunostimulatori
immunosuppress
agent
chapter
concentr
immunostimulatori
agent
capabl
enhanc
host
defenc
mechan
provid
protect
infect
synonym
term
immunomodul
includ
biolog
respons
modifi
immunoaugmentor
immunostimul
immunorestor
mode
action
includ
augment
antiinfecti
immun
cell
immun
sy
tem
encompass
lymphocyt
subset
macrophag
dendrit
natur
killer
nk
cell
mechan
involv
induct
restor
immun
effector
function
tilt
balanc
toward
cytokin
pathway
german
protectiona
divers
array
recombin
synthet
natur
immunomodulatori
prepar
prophylaxi
treatment
variou
infect
avail
today
concis
mindmap
immunomodul
discuss
chapter
summaris
figur
interact
host
infecti
pathogen
complex
divers
intric
regul
cytokin
hormonelik
polypeptid
possess
pleiotrop
properti
crucial
orchestr
appropri
immun
respons
critic
outcom
infectioncertain
cytokin
stimul
product
cytokin
interact
synergist
antagonist
network
cytokin
exhibit
specif
immunomodulatori
properti
enabl
manipul
host
respons
enhanc
overal
immunogen
direct
natur
respons
either
toward
type
type
pathway
type
respons
cell
produc
tumor
necrosi
interleukin
il
requir
effect
develop
cellmedi
immun
respons
intracellular
microb
type
respons
cell
produc
enhanc
humor
immun
tdepend
antigen
necessari
immun
helminth
infect
recent
studi
shown
lymphoid
progenitorderiv
dendrit
cell
also
express
preferenti
induc
type
cell
respons
wherea
myeloid
progenitorderiv
dendrit
cell
express
induc
type
cell
respons
local
system
effect
cytokin
thu
intim
involv
host
control
infect
fig
also
see
chapter
sever
recombin
natur
cytokin
prepar
interferon
granulocyt
colonystimul
factor
alreadi
licens
use
patient
antiinfect
activ
immunomodul
interferon
play
import
role
host
defens
infecti
pathogen
regul
immun
clinic
effect
therapi
use
wide
rang
viral
infect
besid
applic
malign
melanoma
basal
cell
carcinoma
wart
natur
obtain
human
serum
leukocyt
current
licens
treatment
rare
form
cancer
hairi
cell
leukemia
recombin
licens
treatment
chronic
activ
hepat
b
hepat
c
viru
infect
howev
small
subset
patient
hepat
b
around
case
hepat
c
gener
respons
interferon
therapi
also
approv
treat
condyloma
acuminata
caus
human
papilloma
viru
kaposi
sarcoma
patient
hiv
infect
hepat
b
viru
hbv
infect
around
million
peopl
kill
million
peopl
hbv
carrier
die
chronic
hepat
cirrhosi
hepatocellular
carcinoma
present
two
licens
therapi
treat
liver
diseas
caus
infect
hbv
avail
lamivudin
interferon
combin
sever
promis
studi
shown
effect
lamivudineinterferon
lamifn
combin
therapi
gain
increas
favour
treatment
chronic
hepat
b
influenc
tcell
matur
product
cytokin
activ
nk
cellmedi
cytotox
patient
chronic
hepat
b
treat
augment
nkt
cell
cytotox
lymphocyt
liver
fortyeight
week
treatment
patient
show
normal
alanin
aminotransferas
alt
decreas
hbvdna
undetect
level
serum
combin
ribavirin
either
pegyl
state
simultan
substanti
reduc
elimin
sideeffect
normal
associ
administr
ifn
alon
hepat
c
viru
hcv
infect
common
caus
chronic
viral
liver
diseas
lead
indic
liver
transplant
almost
patient
show
recurr
hepat
c
viremia
progress
fibrosi
cirrhosi
liver
transplant
observ
patient
progress
cirrhosi
within
year
transplant
genotyp
consid
resist
therapi
wherea
genotyp
respons
therapi
genotyp
seem
similar
genotyp
respect
box
plu
ribavirin
combin
therapi
found
effect
chronic
hcv
patient
genotyp
virolog
nonrespond
ifn
monotherapi
treatment
durat
week
genotyp
week
genotyp
standard
drawback
short
serum
halflif
rapid
clearanceto
overcom
problem
pegyl
form
ifn
develop
test
clinic
pegyl
form
coval
conjug
monomethoxi
polyethylen
glycol
peg
molecul
pegyl
coval
conjug
branch
monomethoxi
peg
molecul
pegyl
prolong
serum
halflif
hour
rel
standard
hour
greater
polym
size
pegyl
act
reduc
glomerular
filtrat
markedli
prolong
serum
halflif
hour
compar
standard
hour
peginterferon
kd
superior
virolog
efficaci
elicit
histolog
improv
chronic
hcv
genotyp
patient
without
sustain
virolog
respons
peginterferon
kd
effect
patient
infect
viral
genotyp
liver
cirrhosisth
addit
ribavirin
peginterferon
kd
enhanc
therapeut
benefit
patient
hcv
onceweekli
dose
either
pegyl
pegyl
shown
produc
significantli
higher
rate
viral
erad
standard
thriceweekli
therapywith
respect
treatment
chronic
hepat
c
chc
greatest
antihcv
efficaci
achiev
combin
onceweekli
pegyl
ifn
ribavirin
use
ribavirin
pegyl
particularli
pegyl
treatment
chc
infect
involv
first
second
treatment
time
period
least
week
report
clinic
studi
assess
sustain
loss
serum
hcvrna
week
posttreat
regimen
employ
ribavirin
plu
pegyl
week
gave
success
respons
patient
respons
hcv
genotyp
obtain
human
fibroblast
cell
line
licens
use
sever
uncontrol
virusmedi
diseas
case
viral
enceph
herp
zoster
varicella
immunosuppress
patient
indic
viral
infect
inner
ear
loss
hear
standard
treatment
multipl
sclerosi
diseas
without
definit
elucid
etiolog
current
major
mediat
host
resist
acut
chronic
phase
infect
pivot
protect
varieti
intracellular
pathogen
produc
cell
induc
class
class
ii
mhc
product
patient
chronic
granulomat
diseas
unabl
gener
oxid
respiratori
burst
consequ
develop
recur
catalaseposit
bacteri
infect
aureu
pseudomona
cepacia
chromobacterium
violaceum
multicent
clinic
trial
shown
sustain
administr
chronic
granulomat
diseas
patient
markedli
reduc
rel
risk
seriou
infect
licens
therapeut
adjunct
use
patient
chronic
septic
granulomatosi
reduct
frequenc
seriou
infectionsactimmun
tm
prepar
market
chronic
granulomat
diseas
mycobacteri
fungal
infect
major
sideeffect
interferon
therapi
includ
flulik
syndrom
fever
myalgia
headach
fatigu
hypotens
granulocytopenia
thrombocytopenia
also
occur
deleteri
effect
central
nervou
system
cn
particularli
high
dose
observ
high
incid
hivinfect
patient
neutropenia
consider
increas
risk
bacteri
fungal
infectionsgcsf
prepar
filgrastim
rmethugcsf
significantli
enhanc
neutrophil
function
patient
aid
revers
neutropenia
associ
hiv
cytomegaloviru
cmv
infect
filgrastim
grant
licens
extens
cover
treatment
persist
neutropenia
advanc
stage
hiv
infect
one
studi
filgrastimtr
patient
shown
fewer
sever
bacteri
infect
fewer
day
hospit
bacteri
infect
determin
absolut
number
progenitor
cell
progenitor
cell
function
hivinfect
patient
show
gcsf
mainli
increas
number
differenti
myeloid
progenitor
gcsf
gmcsf
use
revers
leukopenia
adjunct
therapi
hivassoci
infectionsin
studi
conduct
european
center
aid
patient
cmv
infect
gcsf
lenograstim
found
suitabl
treatment
ganciclovirinduc
neutropenia
multipl
defici
involv
progress
fungal
infect
neutropen
nonneutropen
cancer
patientsalthough
clinic
experi
still
limit
gcsf
gmcsf
macrophag
csf
show
promis
adjuv
therapi
fungal
infect
highli
activ
antiretrovir
therapi
haart
combin
nucleosid
nonnucleosid
revers
transcriptas
proteas
fusion
drug
inhibitor
improv
morbid
surviv
patient
hiv
infect
current
avail
antiretrovir
agent
suppress
viral
replic
partial
revers
cellular
immun
defect
hiv
patient
combin
antiretrovir
drug
therapi
pivot
benefici
outcom
mani
infect
rekindl
renew
interest
use
immunotherapi
adjunct
treatment
abil
induc
expans
lymphocyt
pool
made
studi
cytokin
treatment
hiv
infect
initi
studi
highdos
therapi
report
decad
ago
sever
limit
toxic
problem
current
approach
decreas
amount
use
intermitt
dose
dramat
increas
cell
count
hivinfect
personsa
major
recent
combinatori
studi
hiv
thu
perform
haart
immunebas
therapi
use
adjunct
therapi
antiretrovir
therapi
may
improv
immun
respons
demonstr
increas
tlymphocyt
count
recent
clinic
trial
regimen
consist
cycl
administ
everi
week
aim
expand
lymphocyt
pool
combin
antiretrovir
treatment
hivinfect
person
lead
rapid
increas
cell
count
patient
cell
count
cell
month
combin
antiretrovir
treatment
receiv
immunotherapi
iu
twice
daili
day
everi
week
cycl
cell
count
increas
significantli
mean
cell
count
cell
cellsmm
increas
naiv
cell
subset
note
immunotherapi
appear
acceler
recoveri
lymphocyt
person
whose
cd
cell
count
fail
increas
rapidli
respons
combin
antiretrovir
treatment
chemokin
histor
regard
leukocyt
chemoattract
capabl
regul
cellular
traffick
inflammatori
site
term
chemokin
abbrevi
chemotact
cytokinesth
major
class
chemokin
constitut
cxc
chemokin
cc
chemokin
c
chemokin
chemokin
accumul
evid
suggest
chemokin
broad
rang
function
includ
macrophag
activ
neutrophil
degranul
dendrit
cell
matur
cell
activ
b
cell
antibodi
class
switchingthu
chemokin
influenc
innat
acquir
phase
immun
respons
chemokin
mediat
angiogenesi
also
play
import
role
develop
immun
circulatori
central
nervou
system
current
chemokin
famili
expand
nearli
ligand
xcl
chemokin
identifi
furthermor
around
chemokin
receptor
includ
cxcr
ccr
xcr
describ
also
see
chapter
human
immunodefici
viru
hiv
infect
wide
rang
human
cell
particular
tropism
cell
monocytemacrophag
cell
lineag
hiv
induc
tcell
dysfunct
cell
apoptosi
decreas
number
tcell
ultim
lead
immunodefici
bcell
dysfunct
caus
hiv
character
hypergammaglobulinemia
polyclon
activ
absenc
specif
antibodi
respons
hiv
entri
host
cell
mediat
receptor
varieti
coreceptor
chemokin
receptor
mainli
discov
necessari
hiv
entri
bind
envelop
glycoprotein
appropri
chemokin
receptor
trigger
conform
chang
facilit
fusion
viral
host
cell
membran
found
vagina
rectal
mucosa
cn
resid
macrophag
mani
tissu
mainli
macrophagetrop
variant
predominantli
make
use
coreceptor
tcelltrop
dualtrop
strain
gener
associ
clinic
manifest
aid
emerg
latenc
sever
year
although
pathogenesi
cn
relat
symptom
normal
associ
mtropic
strain
infect
augment
express
chemokin
macrophag
inflammatori
protein
rant
regul
upon
activ
normal
cell
express
secret
hiv
infect
inhibit
chemokin
chemokinerel
molecul
ligand
chemokin
receptor
function
coreceptor
chemokin
receptor
thu
repres
import
target
intervent
hiv
search
molecul
therapeut
potenti
inhibitor
receptor
intens
chemokin
receptor
belong
rhodopsin
famili
gproteincoupl
receptor
famili
intervent
strategi
base
chemokin
antagonist
could
use
therapeut
hiv
includ
receptorligand
interact
prevent
chemokineglycosaminoglycan
interact
interf
signal
pathway
induc
upon
receptor
activ
modif
receptor
pathway
azaheterocyclylcarboxamid
piperidinyl
pyrrolidin
compound
deriv
target
advoc
recent
treatment
aid
rant
exhibit
clearcut
suppress
effect
hiv
replic
peripher
blood
mononuclear
cell
hivinfect
individu
block
andor
downmodul
rant
antibodi
three
extracellular
domain
recent
modifi
chemokin
small
deriv
molecul
maintain
hivinhibitori
function
devoid
receptoractiv
capabl
gener
mani
infecti
diseas
includ
hiv
malaria
chronic
inflammatori
condit
induc
deleteri
overproduct
proinflammatori
cytokin
gener
intens
interest
develop
agent
block
activ
cytokin
inhibit
tnf
activ
singularli
success
treatment
autoimmun
diseas
monoclon
antibodi
includ
adalimumab
humira
abbott
etanercept
enbrel
amgenwyeth
infliximab
remicad
centocor
use
treatment
rheumatoid
arthriti
receptor
antagonist
kineret
also
recent
licens
anoth
potent
tnf
inhibitor
thalidomid
use
trial
hiv
patient
structur
analogu
thalidomid
improv
inhibitori
activ
current
develop
pentoxifyllin
methylxanthin
usual
use
treatment
peripher
arteri
circulatori
disord
shown
inhibit
tnf
synthesi
current
clinic
trial
ongo
phosphodiesteras
inhibitor
smallmolecul
tnfconvert
enzym
specif
interrupt
signal
pathway
tnf
imiquimod
deriv
tolllik
receptor
tlr
type
transmembran
protein
recogn
microbi
conserv
structur
involv
innat
immun
box
recent
studi
shown
recogn
dsrna
viral
product
wherea
recogn
unmethyl
cpg
motif
frequent
found
genom
bacteria
virus
vertebr
human
express
plasmacytoid
dendrit
cell
pdc
rapidli
synthes
larg
amount
respons
viral
infect
observ
indic
may
play
import
role
combat
viral
infect
interestingli
recogn
synthet
immunomodul
imidazoquinolon
compound
use
viral
infect
imiquimod
fulli
synthet
immun
respons
enhanc
imidazoquinolin
amin
amin
imiquimod
market
aldara
tm
genit
wart
wide
use
basal
cell
carcinoma
actin
keratosi
molluscum
contagiosum
shown
promis
lentigo
maligna
cutan
metastas
malign
melanoma
imiquimod
deriv
resimiquimod
improv
antigenpresent
dendrit
cell
also
act
b
cell
lead
synthesi
antibodi
furthermor
agent
activ
macrophag
cell
via
bind
cell
surfac
receptor
induc
secret
proinflammatori
cytokin
presenc
cytokin
milieu
bias
toward
immun
respons
exploit
clinic
treatment
viral
infect
human
papillomaviru
herp
simplex
viru
molluscum
contagiosum
random
doubleblind
placebocontrol
stud
i
imiquimod
cream
shown
significantli
effect
elimin
genit
wart
patient
clinic
histopatholog
polymeras
chain
reaction
confirm
diagnosi
human
papilloma
viru
infect
treatment
extern
genit
perian
wartstop
appli
imiquimod
cream
reduc
wart
area
hivinfect
patient
fig
propanol
inosin
molar
ratioit
white
cystallin
powder
solubl
water
inosin
portion
isoprinosin
metabol
labil
halflif
rhesu
monkey
found
minut
intraven
minut
oral
administrationisoprinosin
shown
augment
product
cytokin
increas
prolifer
lymphocyt
respons
mitogen
antigen
stimuli
increas
activ
tcell
rosett
induc
tcell
surfac
marker
prothymocyt
isoprinosin
current
licens
europ
treatment
herp
simplex
infect
subacut
scleros
panenceph
acut
viral
enceph
caus
herp
simplex
epsteinbarr
measl
virus
treatment
viral
infect
immunosuppress
patient
isoprinosin
report
minor
cn
depress
neuromuscular
sed
antipyret
activ
pharmacolog
studi
anim
human
isoprinosin
may
caus
transient
nausea
rise
uric
acid
serum
urin
high
dose
last
year
nucleotid
sequenc
contain
nonmethyl
cytosinephosphateguanosin
cpg
dinucleotid
flank
region
two
purin
two
leishmania
markedli
increas
resist
acut
polymicrobi
sepsi
cpg
odn
administ
human
found
well
toler
defensin
famili
structur
relat
cysteinerich
cation
polypeptid
innat
immun
system
produc
respons
microbi
infect
human
anim
insect
plant
six
human
describ
secret
primarili
granulocyt
certain
lymphocyt
wherea
express
intestin
paneth
cell
produc
respons
microbi
infect
mucos
tissu
skin
unusu
circular
minidefensin
identifi
recent
rhesu
monkey
defensin
vertebr
anim
review
elsewher
recent
report
highlight
activ
defensin
whose
structur
charg
resembl
portion
transmembran
envelop
glycoprotein
lymphocyt
certain
immunolog
stabl
individu
secret
solubl
factor
suppress
replic
cell
longterm
nonprogressor
infect
found
secret
cluster
protein
identifi
basi
specif
antibodi
recognit
amino
acid
sequenc
interest
note
shown
effect
suppress
hiv
replic
vitro
year
ago
earlier
studi
synthet
peptid
deriv
region
exhibit
sequenc
similar
defensin
like
defensin
insert
lipid
bilay
peptid
abil
associ
liposom
lymphocyt
membran
antimicrobi
peptid
homolog
rhesu
monkey
circular
minidefensin
prepar
solidphas
peptid
synthesi
name
retrocyclin
retrocyclin
remark
abil
inhibit
provir
dna
format
protect
lymphocyt
vitro
infect
ttropic
mtropic
strain
retrocyclin
interfer
earli
stage
infect
retrocyclinlik
agent
might
use
topic
agent
prevent
sexual
acquir
infect
dna
encod
fuse
proinflammatori
chemoattract
immatur
dendrit
cell
elicit
antibodi
high
titer
virusneutr
activ
use
chemokin
fusion
construct
link
extracellular
domain
via
acid
spacer
peptid
sequenc
augment
immunogenicitythi
construct
elicit
antibodi
effect
neutral
activ
correspond
construct
express
fusion
polypeptid
compris
defensin
viral
antigen
use
produc
immun
respons
subject
treat
viral
infect
includ
hiv
infect
detail
us
depart
health
human
servic
nation
instistut
health
offic
technolog
transferth
viral
antigen
may
hiv
antigen
defensin
may
interest
note
peptid
deriv
envelop
glycoprotein
correspond
predominantli
membraneact
domain
exert
antimicrobi
activ
laboratori
strain
escherichia
coli
listeria
monocytogen
human
fragment
treatment
variou
infect
particularli
respiratori
infect
describ
peptid
claim
use
treatment
infect
caus
pseudomona
aeruginosa
burkholderia
cepacia
gramneg
gramposit
bacteri
infect
yeast
infect
peptid
synthes
test
rang
bacteria
enterococcu
faecali
escherichia
coli
klebsiella
pneumonia
staphylococcu
aureu
streptococcu
pneumonia
p
aeruginosa
b
cepacia
mimp
newer
gener
thymomimet
purin
immunomodul
capabl
enhanc
wide
varieti
immun
responsesit
induc
human
prothymocyt
express
lymphocyt
differenti
marker
receptor
emerg
therapi
synthet
immunomodul
enhanc
mitogeninduc
prolifer
lymphocyt
augment
igm
plaqueform
cell
induc
delayedtyp
hypersensit
normal
impair
respons
suggest
mimp
potenti
immunotherapi
earli
hiv
infect
induc
protect
effect
human
virus
intranas
administr
mimp
improv
surviv
rate
incorpor
mimp
squalanesalin
emuls
confer
complet
protect
influenza
infect
complet
surviv
reduct
viral
load
influenza
challeng
infect
suggest
effect
stimul
mimp
protect
respons
influenza
viru
cell
wall
gramneg
bacteria
contain
endotox
lipopolysaccharid
potent
stimul
immun
system
even
nanogram
quantiti
clinic
applic
endotoxin
howev
hamper
play
major
role
pathophysiolog
gramneg
bacteri
sepsi
concert
effort
made
modifi
endotoxin
possibl
therapeut
use
human
investig
endotox
lipopolysaccharid
led
identif
lipid
import
constitu
endotoxin
molecul
capabl
exhibit
variou
immunopharmacolog
activ
bacteri
lipopolysaccharid
last
ten
year
select
reduct
toxic
endotoxin
whilst
retain
benefici
adjuv
properti
achiev
effect
chemic
treatment
synthesi
nontox
lipid
analogu
prophylact
administr
monophosphoryl
lipid
mpl
nontox
deriv
endotoxin
shown
mitig
sepsi
syndrom
reduc
chemokin
product
pulmonari
hepat
mrna
attenu
product
proinflammatori
cytokin
mpl
use
adjuv
leishmani
malari
tuberculosi
cancer
antigen
administ
thirti
thousand
human
compon
melanoma
melacin
vaccin
approv
use
canada
immunomodul
chemic
defin
new
gener
lipid
analogu
anim
experi
use
aerosol
influenza
viru
show
surviv
group
receiv
subunit
vaccin
alon
could
improv
booster
immun
contrast
vaccin
adjuv
could
confer
complet
protect
alreadi
primari
immun
shown
adjuv
activ
sever
microbi
antigen
alreadi
administ
intramuscularli
human
limit
number
trial
muramyl
peptid
mdp
repres
structur
essenti
mycobacteri
adjuvant
murabutid
mdp
analogu
significantli
reduc
reduc
receptor
secret
high
level
suppress
replic
acut
infect
monocytederiv
macrophag
dendrit
cell
clinic
toler
biolog
effect
immunotherapi
synthet
immunomodul
murabutid
evalu
patient
murabutid
recipi
show
signific
increas
cell
platelet
count
patient
weak
immun
reconstitut
ineffect
viru
suppress
follow
longterm
haart
therapi
ingest
live
microorgan
attain
benefici
effect
health
term
probiot
approach
gain
increas
popular
sever
fortifi
product
avail
consum
probiot
use
condit
diarrhea
candid
vagin
urinari
tract
infect
whole
microb
lactobacillu
casei
bifidobacterium
speci
saccharomyc
boulardii
use
success
prevent
antibioticassoci
diarrhea
treat
diarrheal
ill
caus
bacteria
bifidobacterium
breve
shown
augment
antibodi
product
induc
signific
reduct
frequenc
rotaviru
shed
stool
sampl
infant
major
lactobacillu
speci
present
human
gastrointestin
mucosa
l
plantarum
l
rhamnosu
l
paracasei
found
potent
stimul
bacteri
extract
wide
use
immunomodul
prevent
recurr
infect
respiratori
tract
sever
prepar
contain
bacteri
lysat
eg
bronchomun
luivac
licens
use
europ
exist
larg
bodi
primari
literatur
placebocontrol
doubleblind
clinic
trial
conduct
agentsth
current
concept
mucos
immun
system
postul
stimul
gutassoci
lymphoid
tissu
lead
induct
gener
respons
whole
mucosalassoci
lymphoid
tissu
patient
often
children
recurr
episod
infect
respiratori
tract
ear
nose
throat
treat
oral
bacteri
lysat
case
frequenc
sever
infect
report
reduc
physician
patient
consid
treatment
benefici
interest
mani
studi
report
decreas
antibiot
consumpt
bacteri
lysatetr
patientsa
multicent
studi
oral
bacteri
lysat
immunomodul
lw
involv
recurr
respiratori
tract
infect
patient
countri
europ
latin
america
asia
recent
conduct
overal
reduct
least
number
sever
durat
respiratori
tract
infect
number
antibiot
symptomat
treatment
number
day
absent
school
work
report
hemodialysi
patient
suffer
sever
immun
defect
increas
risk
develop
bacteri
infect
particularli
respiratori
tract
doubleblind
placebocontrol
prospect
studi
oral
immunotherapi
immunomodul
bacteri
extract
significantli
reduc
number
patient
respiratori
tract
infect
consequ
number
antibiot
treatment
cours
immunomodul
polysaccharid
poli
pggglucan
market
betafectin
found
use
prevent
mortal
abscess
format
associ
experiment
intraabdomin
sepsi
absenc
antimicrobi
therapi
safeti
efficaci
pggglucan
surgic
patient
high
risk
postop
infect
underw
major
thorac
abdomin
surgeri
show
pggglucan
significantli
fewer
infecti
complic
decreas
intraven
antibiot
requir
shorter
intens
care
unit
length
stay
prophylaxi
prevent
staphylococc
wound
infect
could
synergist
enhanc
ad
pggglucan
antibiot
cefazolinperiop
administr
pggglucan
reduc
seriou
postop
infect
death
highrisk
noncolorect
oper
lentinan
chemic
well
defin
branch
isol
edibl
japanes
mushroom
lentinu
edod
shiitak
mushroom
immunomodul
properti
licens
adjunct
antitumor
therapi
japan
experiment
prevent
exist
emerg
infecti
diseas
multidisciplinari
multifacet
endeavorth
tradit
treatment
infect
focus
antimicrobi
agent
induct
specif
immun
defens
forefront
immunotherapeut
come
decad
modul
host
respons
infecti
diseas
select
stimul
discret
lymphocyt
subpopul
import
protect
effector
mechan
given
infect
suitabl
immunomodul
play
increasingli
import
role
polar
immun
respons
readili
achiev
irrespect
genet
bia
host
natur
protein
antigen
choic
appropri
immunomodul
major
promis
new
immunomodul
lie
broad
activ
divers
microbi
pathogen
mode
action
distinctli
differ
direct
microbicid
action
establish
antibiot
antivir
antifungalsadjuv
cytokin
gmcsf
use
shorten
durat
treatment
also
possibl
control
deleteri
overproduct
inflammatori
cytokin
observ
certain
diseas
state
sever
immunomodulatori
agent
activ
innat
nonantigenspecif
host
defens
recent
recogn
immunomodulatori
agent
cpg
dna
increasingli
find
benefici
role
prevent
infect
noteworthi
around
biotechnolog
protein
drug
includ
recombin
protein
monoclon
antibodi
current
avail
repres
quarter
drug
introduc
worldwid
recent
new
methodolog
current
avail
potenti
identifi
novel
target
foster
develop
individu
tailor
immunomodulatori
drug
treatment
human
genom
project
indic
human
genom
contain
proteinencod
gene
estim
distinct
proteinsit
would
requir
protein
develop
drug
abl
provid
hundr
novel
therapeut
agent
immunomodul
becom
viabl
adjunct
establish
modal
offer
novel
approach
treatment
infecti
diseas
come
decad
centuri
avail
vast
array
recombin
synthet
immunomodul
signific
mileston
toward
develop
effect
therapi
infecti
diseasesthi
evinc
licens
sever
recombin
human
cytokin
includ
erythropoietin
clinic
use
patient
divers
combin
interferon
cytokin
treatment
variou
infect
propos
other
includ
variou
chemokin
synthet
cpg
oligodeoxynucleotid
glucan
extens
investig
clinic
preclin
studi
consider
advanc
made
compound
exhibit
cytokin
inhibitori
properti
use
new
treatment
infecti
inflammatori
diseas
mani
major
develop
current
trend
highlight
review
novel
strategi
base
engin
cytokin
inhibitor
pois
revolution
therapeut
option
conting
upon
scientif
evid
rather
dictat
discurs
empiric
come
decad
